BRCA1 and ovarian carcinoma: We used the HR-competent cell lines SKOV3 and OVCAR3 to further investigate the combinatorial effects of DFMO, rucaparib, and cisplatin in ovarian cancer cells with wild-type BRCA1/2 functionality [45].